Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec, Bayer CropScience Reach Screening Deal

NEW YORK (GenomeWeb News) – Caprotec Bioanalytics has reached an agreement to use its technology to screen an undisclosed new active ingredient from Bayer CropScience.

The deal announced today calls for Berlin-based Caprotec to use its Capture Compound Mass Spectrometry technology to profile interactions of Bayer's ingredient in the relevant biological system. The technology, based on tri-functional molecules called capture compounds, can be used to define and confirm drug targets and discover off-target proteins that cause side effects.

Financial and other details were not disclosed.

In the spring, Caprotec announced it had raised $1.4 million to leverage its CCMS technology into new markets and to execute partnerships with large pharma firms.